Equity
€360,806 ▲ 46.9%
Equity rose in 2025 from €245,674 to €360,806.
ORIANESTH
Lifetime
18 annual accounts with figures on one time axis, 25 filings since 2001peak €290,936 (2025)
€290,936▲ 8.0%
lowest -€110,925 (2019)
€115,132▲ 57.9%
peak €501,460 (2016)
€360,806▲ 46.9%
€452,800▲ 33.5%
Board2 names since 2001
2 directors and 1 other
Documentsfilings and deeds
31-08-202631 days late
2025micro format
Result from €72,937 to €115,132Equity from €245,674 to €360,806Debts from €339,226 to €452,800Investments €133,630Cash from €20,041 to €95,700
Key points
from the 2025 annual accountsTurnover
≈ €440,000 estimated
The micro format states no turnover.
Debts
€452,800 ▲ 33.5%
Debts rose by €113,574 in 2025.
Investments
€148,272 7.9 × depreciation
Green is investment, beige is depreciation.
Filings
25 annual accounts since 2001
Nine of the last ten came late. The 2022 accounts came latest: 70 days after the end of the period.
Position in the sector
€290,936
Higher gross margin than 84% of companies in human health. Sector median €112,715 · 21,315 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 20,135 companies had the same profile as ORIANESTH has now. Each dot stands for 51 companies, two years later.
95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,135 companies, not a prediction for ORIANESTH. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0474176184
2 directors reappointed
(director) and (director) · Permanent representative: · “L'objet de la société par laquelle le médecin exerce son activité professionnelle doit être compatible avec…” (deed in French) · General meeting of 07-12-2023 · Gazette deed
Incorporation
published on 07-03-2001 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ORIANESTH Les Bons Villers | €813,606 | €290,936 | 44.3% | - |
| DOCTEUR FRANCIS AUPAIX Charleroi | €795,549 | €283,593 | 82.3% | - |
| DAREVAL Mons | €798,655 | €306,585 | 51.4% | - |
| J.B. MEDICAL Chimay | €799,224 | €325,064 | 90.9% | - |
| DR. YANNI Mons | €707,150 | €278,371 | 94.6% | - |
| DR. MARC DETOLLENAERE Koksijde | €834,694 | €297,691 | 89.3% | - |
| CABINET MEDICAL DU DOCTEUR CLAUDE LEYRE Spa | €764,734 | €291,276 | 90.4% | - |
These companies have the same main activity as ORIANESTH: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €707,000 and €835,000, founded between 2000 and 2003.
Official details
Source: KBO- Status
- Active since 26-02-2001Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Financial year end
- 31 December
- Peppol
- Reachable since 21-11-2025
Insights on ORIANESTH
ORIANESTH files the micro format. That format states no turnover. The gross margin rose from €163,501 in 2008 to €290,936 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ORIANESTH
- What is the company number of ORIANESTH?
- The company number of ORIANESTH is 0474.176.184. The VAT number is the same number with BE in front: BE 0474.176.184.
- Where is ORIANESTH based?
- The registered office is at Rue Commune 8, 6210 Les Bons Villers.Company details
- What does ORIANESTH do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of ORIANESTH?
- ORIANESTH is a private limited company (BV).
- When was ORIANESTH founded?
- ORIANESTH was founded on 26-02-2001.
- Is ORIANESTH still active?
- Yes, ORIANESTH is an active enterprise in the KBO register.
- What is the turnover of ORIANESTH?
- The turnover in financial year 2025 is ≈ €440,000. This figure is estimated from the gross margin of €290,936 and 30 comparable companies (NACE 86220). It probably lies between €400,000 and €610,000.Financials
- Is ORIANESTH profitable?
- In financial year 2025, ORIANESTH made a profit of €115,132.
- Where can I find the annual accounts of ORIANESTH?
- ORIANESTH filed 25 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ORIANESTH due?
- ORIANESTH must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.